Search

Your search keyword '"García Del Muro X"' showing total 185 results

Search Constraints

Start Over You searched for: Author "García Del Muro X" Remove constraint Author: "García Del Muro X"
185 results on '"García Del Muro X"'

Search Results

1. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

2. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy

3. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

4. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

7. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)

10. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

16. 704P Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study

17. Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

18. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

20. METEOR Studie: Analyse des Gesamtüberlebens (OS) basierend auf der frühen Tumorvolumenreduktion (eTS) in der Phase III Studie von Cabozantinib (Cabo) versus Everolimus (Eve) beim fortgeschrittenen Nierenzellkarzinom (RCC)

22. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group

24. METEOR Studie: Analyse des Gesamtüberlebens (OS) basierend auf der frühen Tumorvolumenreduktion (eTS) in der Phase III Studie von Cabozantinib (Cabo) versus Everolismus (Eve) beim fortgeschrittenen Nierenzellkarzinom (RCC)

25. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

27. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group

30. O5 - Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study

31. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study

34. LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

35. 667P Impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on overall survival (OS) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel (D) plus androgen-deprivation therapy (ADT)

36. 655P Prognostic significance of docetaxel (D) plus androgen-deprivation therapy (ADT) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) according to extent of disease: A study of real-world data

37. 698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

38. 218 - Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy

39. SEOM clinical guideline for treatment of kidney cancer (2017)

40. LBA14_PR - IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

47. Risk-adapted treatment in clinical stage I testicular seminoma: The third Spanish Germ Cell Cancer Group study

49. Integrating Genotype in Risk Classification for Gist Recurrence. a Spanish Group for Sarcoma Research (Geis) Study

Catalog

Books, media, physical & digital resources